Regulatory Approval (ANDA)
Alembic Pharmaceuticals Receives USFDA Tentative Approval for Darolutamide Tablets 300 mg
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals Limited has received tentative approval from the USFDA for its ANDA Darolutamide Tablets 300 mg, used in prostate cancer treatment. The product has an estimated U.S. market size of US$ 3,155 million for the twelve months ending March 2026.
PRICE-SENSITIVE TRIGGER
Event: USFDA Tentative Approval Received
Type: Regulatory Approval (ANDA)
Impact: Positive
Immediate Effect: The approval strengthens Alembic’s U.S. generics pipeline and enhances future commercialization opportunities in the oncology segment.
Key Metrics:
- Product: Darolutamide Tablets, 300 mg
- Approval Type: USFDA Tentative Approval
- Estimated U.S. Market Size: US$ 3,155 Million
- Total USFDA ANDA Approvals: 238
- Final Approvals: 219
- Tentative Approvals: 19
Highlight:
- Label: U.S. Oncology Opportunity
- Value: US$ 3,155 Million estimated market size
What Happened ?
Alembic Pharmaceuticals Limited announced that it has received tentative approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Darolutamide Tablets 300 mg.
The approved ANDA is therapeutically equivalent to Bayer’s Nubeqa Tablets 300 mg. Darolutamide is indicated for treatment of multiple prostate cancer conditions including non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
The company highlighted that the product addresses a large U.S. market opportunity according to IQVIA data.
key highlights
Approval Details & Market Opportunity:
- Alembic received USFDA tentative approval for Darolutamide Tablets 300 mg.
- The product is equivalent to Bayer’s Nubeqa Tablets 300 mg.
- Darolutamide is an androgen receptor inhibitor used in prostate cancer treatment.
- The drug is indicated for nmCRPC and mCSPC patient categories.
- Estimated U.S. market size stands at US$ 3,155 million for the twelve months ending March 2026.
- Alembic now has cumulative 238 ANDA approvals from USFDA.
- The company has 219 final approvals and 19 tentative approvals.
- The approval further strengthens Alembic’s oncology and U.S. generics portfolio.
Note:
- Tentative approval generally indicates that the product satisfies regulatory requirements but commercial launch may depend on patent or exclusivity conditions.
Risk Analysis
Key Risks
- Tentative approval does not guarantee immediate commercial launch.
- Patent and exclusivity restrictions may delay market entry.
- U.S. generics market faces pricing pressure and intense competition.
- Regulatory compliance and manufacturing consistency remain critical.
- Actual market capture may vary from estimated opportunity size.
Worst Case Scenario
- Delay in final approval conversion or adverse pricing competition could reduce expected revenue contribution from the product launch.
Risk Level: Medium
Company Commentary
- Alembic Pharmaceuticals received USFDA tentative approval for Darolutamide Tablets 300 mg.
- The product is therapeutically equivalent to Bayer’s Nubeqa Tablets.
- The estimated U.S. market size is US$ 3,155 million.
- Alembic currently holds 238 cumulative ANDA approvals from USFDA.
- The company continues expanding its regulated market pharmaceutical portfolio.
Official Exchange Filing: Alembic Pharmaceuticals Limited